

# Contents

|  |           |
|--|-----------|
| <b>List of Contributors</b>  | <b>xi</b> |
| <b>1 Basics of Clinical Metabolic Research</b>   | <b>1</b>  |
| <i>Michael Roden</i>   |           |
| <b>2 Methods for the Assessment of <math>\beta</math>-Cell Function <i>In Vivo</i></b> | <b>7</b>  |
| <i>Andrea Mari and Giovanni Pacini</i>   |           |
| Introduction   | 7         |
| Methods for insulin secretion <i>in vivo</i>   | 7         |
| $\beta$ -cell response characteristics   | 9         |
| $\beta$ -cell function tests   | 12        |
| Modelling methods  | 19        |
| $\beta$ -cell function and insulin sensitivity   | 20        |
| Comparative evaluation of methods  | 21        |
| Conclusion   | 24        |
| <b>3 Assessment of Insulin Sensitivity from Steady-State and Dynamic Tests</b>         | <b>27</b> |
| <i>Giovanni Pacini and Andrea Mari</i>   |           |
| Introduction   | 27        |
| Insulin sensitivity from steady-state tests  | 28        |
| Insulin sensitivity from dynamic tests   | 31        |
| Conclusion   | 37        |
| <b>4 Glucose Clamp Techniques</b>  | <b>43</b> |
| <i>Attila Brehm and Michael Roden</i>  |           |
| Introduction   | 43        |
| Basic principles of the euglycaemic hyperinsulinaemic clamp technique                  | 49        |
| Methodology  | 57        |
| Reproducibility of insulin sensitivity obtained from clamp tests                       | 64        |
| Safety considerations for hyperinsulinaemic euglycaemic clamp test                     | 65        |
| Modifications of the euglycaemic hyperinsulinaemic clamp test protocol                 | 65        |
| Conclusion   | 67        |

|          |   |            |
|----------|---|------------|
| <b>5</b> | <b>Methods of Assessment of Counterregulation to Hypoglycaemia</b>                        | <b>77</b>  |
|          | <i>Pratik Choudhary, Ming Ming Teh and Stephanie A Amiel</i>                              |            |
|          | Introduction  | 77         |
|          | Definitions   | 78         |
|          | Pathophysiology   | 79         |
|          | Documentation of hypoglycaemia experience   | 81         |
|          | Investigating the pathogenesis of problematic hypoglycaemia                               | 85         |
|          | Hypoglycaemic stimuli for research  | 89         |
|          | Measurement of physiological responses  | 93         |
|          | Conclusion  | 97         |
| <b>6</b> | <b>Glucose Kinetics: Measurement of Flux Rates</b>  | <b>105</b> |
|          | <i>Jerry Radziuk and Susan Pye</i>  |            |
|          | Introduction  | 105        |
|          | Measurement of glucose production and uptake by the liver – tissue balance techniques     | 106        |
|          | Properties of glucose tracers   | 107        |
|          | Measurement of glucose production and uptake by the liver – systemic techniques           | 111        |
|          | Conclusion  | 122        |
|          | Acknowledgements  | 122        |
| <b>7</b> | <b>Xenobiotics as Probes of Carbohydrate Metabolism</b>                                   | <b>125</b> |
|          | <i>Bernard Landau</i>   |            |
|          | Introduction  | 125        |
|          | Glucuronidation   | 125        |
|          | Glutamination   | 128        |
|          | Ribosylation  | 130        |
|          | Acetylation   | 131        |
|          | Glycination   | 132        |
| <b>8</b> | <b>Tracing Hepatic Glucose and Glycogen Fluxes with <math>^2\text{H}_2\text{O}</math></b> | <b>139</b> |
|          | <i>John G Jones</i>   |            |
|          | Introduction  | 139        |
|          | Methodology   | 140        |
|          | Theoretical considerations  | 142        |
|          | Quantifying hepatic glucose and glycogen metabolism                                       | 145        |
|          | Conclusion  | 148        |
| <b>9</b> | <b>Lipid Kinetics</b>   | <b>151</b> |
|          | <i>John M Miles and Robert H Nelson</i>   |            |
|          | Introduction  | 151        |
|          | Tracers for the study of adipose tissue lipolysis   | 151        |
|          | Tracers for the study of triglyceride-rich lipoprotein kinetics                           | 156        |
|          | Conclusion  | 164        |
|          | Acknowledgements  | 164        |

|  |            |
|--|------------|
| <b>10 Protein and Amino Acid Kinetics</b>                                  | <b>169</b> |
| <i>Stephen F Previs, Danielle A Gilge and Nadia Rachdaoui</i>              |            |
| Introduction   | 169        |
| Measuring amino acid turnover  | 170        |
| Measuring protein turnover   | 175        |
| Proteome dynamics  | 181        |
| Urea kinetics  | 182        |
| Determining the molecular control of protein dynamics                      | 185        |
| Conclusion   | 186        |
| Acknowledgements   | 187        |
| <br>   |            |
| <b>11 Assessment of Metabolic Fluxes by <i>In Vivo</i> MR Spectroscopy</b> | <b>193</b> |
| <i>Martin Krššák and Michael Roden</i>                                     |            |
| Phenomena of nuclear magnetic resonance – imaging and spectroscopy         | 193        |
| Skeletal muscle  | 198        |
| Liver  | 207        |
| Brain  | 213        |
| Conclusion   | 214        |
| <br>   |            |
| <b>12 Positron Emission Tomography in Metabolic Research</b>               | <b>223</b> |
| <i>Pirjo Nuutila, Patricia Iozzo and Juhani Knuuti</i>                     |            |
| Introduction   | 223        |
| Tracers for metabolic imaging  | 224        |
| Principles of modeling   | 225        |
| Future perspectives  | 232        |
| <br>   |            |
| <b>13 Assessment of Body Fat Content and Distribution</b>                  | <b>237</b> |
| <i>Martin Krššák</i>   |            |
| Introduction   | 237        |
| Measurement techniques   | 237        |
| Body fat distribution and insulin resistance                               | 247        |
| <br>   |            |
| <b>14 Tissue Biopsies in Diabetes Research</b>                             | <b>265</b> |
| <i>Kurt Højlund, Michael Gaster and Henning Beck-Nielsen</i>               |            |
| Introduction   | 265        |
| Percutaneous needle biopsy of skeletal muscle                              | 266        |
| Biopsy procedure and sample handling                                       | 267        |
| Discomfort and complications of needle biopsy                              | 269        |
| Advantages and limitations of needle biopsy                                | 270        |
| Application of muscle biopsy in diabetes                                   | 270        |
| Morphology of skeletal muscle  | 273        |
| Application of muscle morphology in type 2 diabetes                        | 273        |
| Human myotube cultures   | 276        |
| The cell culture principle of human myotubes                               | 277        |
| Advantages of human myotubes   | 279        |

|  |            |
|--|------------|
| Limitations of human myotubes                                    | 279        |
| Application of myotubes in diabetes research                     | 281        |
| Conclusion   | 282        |
| <br>   |            |
| <b>15 Assessment of Vascular Function</b>                        | <b>289</b> |
| <i>Johannes Pleiner and Michael Wolzt</i>                        |            |
| Basic theoretical concepts                                       | 289        |
| The vascular endothelium   | 289        |
| Strain gauge plethysmography                                     | 290        |
| Flow Mediated Dilation (FMD) of the brachial artery              | 295        |
| Intima media thickness of the carotid artery                     | 299        |
| Assessment of arterial stiffness                                 | 303        |
| <br>   |            |
| <b>16 Cardiovascular Autonomic Function Testing</b>              | <b>311</b> |
| <i>Dan Ziegler</i>   |            |
| Introduction   | 311        |
| Prognosis  | 312        |
| Epidemiology   | 312        |
| Clinical features  | 313        |
| Diagnostic assessment  | 316        |
| <br>   |            |
| <b>17 Nerve Function Testing</b>                                 | <b>325</b> |
| <i>Haris M Rathur and Andrew J M Boulton</i>                     |            |
| Introduction   | 325        |
| Clinical Assessment  | 325        |
| Clinical screening devices (not requiring external power source) | 328        |
| Quantitative sensory testing                                     | 330        |
| Electrophysiology  | 332        |
| Other methods of assessment                                      | 334        |
| Non-invasive assessment  | 335        |
| Conclusion   | 336        |
| <br>   |            |
| <b>18 Kidney Function</b>  | <b>341</b> |
| <i>Sally M Marshall</i>  |            |
| Introduction   | 341        |
| Glomerular function  | 341        |
| Tubular function   | 346        |
| Renal haemodynamics  | 346        |
| Renal structure  | 347        |
| Genetic studies  | 348        |
| Provocation tests  | 348        |
| Functional magnetic resonance imaging and spectroscopy           | 349        |
| Conclusion   | 350        |

|   |            |
|---|------------|
| <b>19 Techniques for the Investigation of the Eye in Diabetes</b>                 | <b>357</b> |
| <i>Ayad Al-Bermani and Roy Taylor</i>   |            |
| Introduction  | 357        |
| Visual acuity   | 357        |
| Fluorescein angiography of the fundus   | 359        |
| Optical coherence tomography (OCT)  | 362        |
| <br>  |            |
| <b>20 Basics of Molecular Genetics: Lessons from Type 2 Diabetes</b>              | <b>367</b> |
| <i>Leif Groop and Charlotte Ling</i>  |            |
| Introduction  | 367        |
| Genetic risk  | 367        |
| Genetic variability   | 368        |
| Mapping genetic variability   | 369        |
| Future directions   | 375        |
| <br>  |            |
| <b>21 Good Clinical Practice: Friend or Foe?</b>                                  | <b>377</b> |
| <i>Christian Joukhadar and Markus Müller</i>                                      |            |
| Introduction  | 377        |
| Scientific misconduct   | 378        |
| Publication bias  | 378        |
| Institutional review board/independent ethics committee                           | 379        |
| Protocol and informed consent   | 380        |
| Special populations   | 381        |
| Serious adverse event reporting   | 382        |
| Monitoring and inspection   | 383        |
| Conclusion  | 384        |
| <br>  |            |
| <b>22 Statistical Considerations in Diabetes Trials</b>                           | <b>387</b> |
| <i>Irene M Stratton and Carole A Cull</i>   |            |
| Introduction  | 387        |
| Requirements  | 388        |
| Study design and power calculations   | 388        |
| Biochemical and clinical measurements   | 388        |
| Demographics  | 389        |
| Cross-over studies  | 390        |
| Long term studies   | 390        |
| Specialised trial designs   | 390        |
| Reporting of study protocols  | 390        |
| Identification and measurement of outcome measures and surrogate outcome measures | 391        |
| Adjudicated endpoints   | 391        |
| Validation of data  | 391        |
| Other sources of bias and error   | 391        |
| Analysis  | 392        |
| <br>  |            |
| <b>Index</b>  | <b>395</b> |

